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S~mmar~ 
To study the effects of volume overload and renal fai lure on 
plasma levels of immunoreactive atr ial natriuretic hormone (IR-ANH), 
we measured levels of this hormone in normal subjects, in patients 
with advanced chronic renal fai lure (CRF) with and without 
c l in ica l ly  evident volume overload, and in patients with end-stage 
renal disease (ESRD) treated with chronic hemodialysis. The levels 
were 13 * 2 pmo111 in normal volunteers, 77 * 24 pmolll in patients 
with CRF without volume overload, and 219 * 50 pmol/l in patients 
with CRF and c l in ica l ly  evident volume overload (analysis of 
variance, p < 0.001, ~ = 0.05 compared to normals). In patients 
with ESRD, the levels of IR-ANH were 145 * 46 pmolll before dialysis 
and decreased to 87 * 31 after dialysis (p < 0.025). No correlation 
was found between the decrease in IR-ANH levels and the decrease in 
weight during dialysis. A signif icant positive correlation was 
found between the IR-ANH levels and blood urea nitrogen in patients 
with CRF (r = 0.658, p < 0.01). 
Volume overload appears to be the most important stimulatory 
factor for ANH secretion in renal fai lure patients but other 
mechanisms, especially a decrease in metabolic clearance, may also 
contribute to elevated plasma levels. The increased secretion of 
ANH in patients with renal fai lure may be an important adaptive 
response to volume overload and hypertension. 
Atrial natr iuretic hormone (ANH) is a term for a group of peptides with 
potent natr iuret ic,  diuretic and vasorelaxant act iv i ty in animals and 
humans (1-4). Recently, measurable levels of ANH have been found in rat and 
human plasma (5-11) and specific membrane receptors have been described in 
arterial smooth muscle, renal and adrenal cortical tissue (12,13). Based on 
these data the hormonal role of this peptide seems to be assured and we wil l  
use the term ANH in this paper. 
The mechanisms which regulate secretion of ANH are s t i l l  largely unknown, 
but an increase in atr ial pressure, probably by atr ial stretch, is a potent 
stimulator of ANH release (7). Volume overload has beer shown to enhance the 
ANH secretion in both animals (7) and humans (i0,14). 
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To evaluate the effect of volume overload and renal fai lure on ANH 
secretion we measured the levels of immunoreactive ANH (IR-ANH) in normal 
volunteers, patients with advanced chronic renal fai lure (CRF), and patients 
with end-stage renal disease (ESRD) on maintenance hemodialysis. 
Methods 
Subjects 
Thirty one normal volunteers (12 women and 19 men) aged 19-39 years (mean 
SE 25 * 1) had a single blood sample drawn in the recumbent position. 
Thirteen patients (4 women and 9 men) aged 23-73 (mean 45 * 5) on a chronic 
hemodialysis program were studied 3 days after their previous treatment. All 
had cl inical evidence of volume overload. Subjects had all eaten 30 to 90 
minutes prior to dialysis. One blood sample was drawn from the venous line 
before dialysis and another blood sample was drawn from the same line 
10 minutes before the end of the dialysis. In nine of the 13 patients an 
additional blood sample was drawn from the arterial line 10 minutes before the 
end of the dialysis. In five of the dialysis patients, plasma volume was 
measured prior to and 10 minutes before the end of the dialysis using albumin 
iodinated with 1311 (15). 
The cause of renal fai lure in the 13 patients with ESRD was 
glomerulonephritis in seven patients, chronic pyelonephritis in three 
patients, and in ters t i t ia l  nephritis, diabetic nephropathy and nephrosclerosis 
in one patient each. One patient had undergone bilateral nephrectomy. The 
patients had been treated with chronic hemodialysis for 3 months to 11 years 
before the study (mean 4.0 m 1.2 year, median 1.5 years). The dialyzers used 
included Cordis-Dow 135 SCE for 9 patients, and CA 110, CA 90, SCE 90 and 
Hospal 3000 for one patient each. Standard dialysate compositions of 
136-140 mEq/l sodium, 0-3 mEq/l potassium, 3.25-3.5 mEq/l calcium, and 
1-1.5 mEq/l magnesium were used. 
Another group of 16 patients with CRF was also studied. All were males 
aged 37-86 years (mean 61 * 3) and none of them was treated with dialysis. 
Their blood urea nitrogen (BUN) levels were 47-124 mg/dl (mean 79 * 5). Seven 
had diabetic nephropathy, three had nephrosclerosis, two had analgesic 
nephropathy, and one each had polycystic kidney disease, IgA nephropathy, 
obstruction and Henoch-Schonlein syndrome as the cause for  their renal 
fai lure. Eight of the 16 patients had clear evidence of volume overload 
(prominent pedal edema). Patients with renal fai lure were on a wide variety 
of medications including diuretics (for the CRF group), other antihypertensive 
agents, calcium carbonate, phosphate binders and others. 
The study was approved by the Human Studies Committee of the University 
of Michigan Hospitals. 
Assay methods 
Plasma IR-ANH levels were measured by radioimmunoassay (9). In b r ie f ,  
blood samples, drawn into EDTA tubes, were put on ice and plasma was separated 
wi th in 30 min of sampling. Plasma was extracted through C18 Sep Pak 
cartr idges (Waters Associates, Mi l ford,  MA) and IR-ANH levels were measured by 
radioimmunoassay. The in t ra -  and interassay var iat ions were 8.6 and 14.2% 
respect ively.  Serial d i lu t ions of plasma samples from renal fa i l u re  patients 
were closely paral le l  with the standard curve (Fig. I ) .  
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FIG. 1 
Serial dilutions of plasma samples from patients with ESRD and CRF 
compared with the standard curve for IR-ANH using logit- log 
transformation. 0 [ ] -  ESRD patients, Z~- patients with CRF, 
• - standard curve. 
Stat ist ical methods 
The results are expressed as mean * standard error. Analysis of variance 
(ANOVA) with Newman-Keuls test (a = 0.05), paired Student's t test, and paired 
and unpaired Wilcoxon test (for data not normally distributed) with 
Bonferroni's protection were used. The CLINFO computer system of the 
University of Michigan Clinical Research Center was used for data storage and 
analysis. 
Results 
The distribution of IR-ANH levels in different groups of patients and 
volunteers is shown in Fig. 2. There was a signif icant va r iab i l i t y  between 
groups (ANOVA, p < 0.001). Patients with CRF and volume overload had IR-ANH 
levels s igni f icant ly higher than normals or patients with CRF without c l in ical  
evidence of volume overload (NKT, a = 0.05). The levels of IR-ANH before 
dialysis were s igni f icant ly  higher than those in normal volunteers (NKT, 
a = 0.05). Patients with CRF without cl in ical  evidence of volume overload had 
plasma IR-ANH levels which were not s igni f icant ly higher than normal. 
1638 ANH in Renal Failure Vol. 41, No. 13, 1987 
600  - 
500  
4OO 
. . I  
0 
E 
Q" 3 0 0  
- r  
Z 
I 







• ! ~:~:~:~:i:~~;i~::::::::::::::~!~i:i~i:i:i:1:i:~:~:~:~:~:~:~::~i:i:i:i~i~i~i:~::::::::::::::::i:i~i:i:i~i:i:i:i:i:i:~:  i:ii 
N o r m a l s  P r e -  C R F  p a t i e n t s  
D i a l y s i s  without with 
• d • m •  • d • m •  
FIG. 2 
Distribution of IR-ANH levels in patients with renal fa i lure and normal 
volunteers, p < 0.001, ANOVA; o s ign i f icant ly  di f ferent than normals, 
+ s ign i f icant ly  different than CRF patients without c l in ica l  evidence of 
volume overload. Shaded area represents mean * 2 S.D. for normal 
volunteers; mean * S.E. are shown for patients. 
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Mean blood pressure, heart rate and weight before and after dialysis are 
shown in Table 1. Six of the patients were hypertensive (mean B.P. > 107) 
before dialysis. Blood pressure returned to normal during dialysis in f ive of 
the six. There was a significant decrease in mean blood pressure and body 
weight during dialysis (paired t test, p < 0.01). The decrease in heart rate 
was close to being s ta t is t ica l ly  significant (paired t test, p = 0.058). 
Table 1. 
Body weight, heart rate and mean blood pressure 
in ESRD patients before and after dialysis 
Weight Heart Rate Mean B.P. 
Pre-dialysis 64.5*2.5 85*3 104,5 
Post-dialysis 62.2*2.6* 91,4 94*3* 
* p < 0.01, paired Student's t test compared to pre-dialysis 
Plasma IR-ANH levels in ESRD patients before and after dialysis are shown 
in Fig. 3. There was no signif icant correlation of basal IR-ANH level with 
either age or blood pressure. The IR-ANH levels decreased signif icantly from 
145 * 46 pmol/l before dialysis to 87 * 31 pmol/l after dialysis and both 
levels were signif icant ly higher than those in normal volunteers (paired and 
unpaired Wilcoxon test with Bonferroni's protection p < 0.025). Nine ESRD 
patients showed a prominent decrease in IR-ANH levels after the dialysis, 
three had only minimal changes and in one patient the IR-ANH levels actually 
increased after the dialysis. This patient had the highest heart rate after 
the dialysis (126 beats per minute) and her mean blood pressure increased 
following the dialysis in contrast to the prominent decreases which occurred 
after dialysis in the other ESRD patients. There was no significant 
difference in IR-ANH levels between hypertensive and normotensive patients. 
Nine patients had simultaneous arterial and venous line samples drawn 
just before the end of the dialysis. There was an 8% decrease in IR-ANH 
levels in blood from the venous line as compared to the arterial l ine 
(From 59~11 to 54"11 pmol/l). This decrease was s ta t is t ica l ly  signif icant 
(paired t test, p<O.01). The calculated diffusive clearance of IR-ANH by the 
dialyzer was 21 ml/min at an average blood flow rate of 246 ml/min. 
There was no correlation between the decrease in IR-ANH levels and the 
decrease in body weight during the dialysis in ESRD patients. There was also 
no correlation between the decrease in plasma volume and the decrease in 
IR-ANH (data not shown). 
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Dist r ibut ion of IR-ANH levels in ESRD patients before and after 
d ia lys is ,  o - p < 0.025, Wilcoxon test with Bonferroni's protection 
compared to normals. * - p < 0.025, paired Wilcoxon test with 
Bonferroni's )rotection compared to pre-dia lys is.  
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In patients with CRF there was a signficant correlation between IR-ANH 
and BUN (linear regression analysis, r = 0.658, p < 0.01 - Fig. 4). There was 
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FIG. 4 
IR-ANH levels as a function of BUN in patients with CRF. r = 0.658 
p < 0.01, linear regression analysis. O -  patients with edema, 
• - patients without edema. 
Discussion 
This study shows that patients with renal fai lure have elevated levels of 
IR-ANH. This applies to patients with ESRD on chronic hemodialysis as well as 
to patients with CRF and volume overload. This lat ter  group had IR-ANH levels 
which were the highest of al l  our study groups (219 * 50 pmol/l). Patients 
with CRF without volume overload had plasma IR-ANH levels of 77 * 24 pmol/l 
and six of eight had plasma levels higher than the mean * 2 SD for normal 
volunteers (higher than 31 pmo]/l). This elevation was not significant when 
compared to normal volunteers (13 * 2 pmol/l). BUN levels higher than 
70 mg/dl were associated with elevated levels of IR-ANH. In a pediatric 
study, Rascher et al.  (16) reported that children with CRF who had no 
evidence of volume expansion had IR-ANH levels s l ight ly  but not s igni f icant ly 
higher than normal. Two of six children with CRF had IR-ANH levels which were 
higher than normal but their renal function was not reported. We would 
postulate that volume overload may be undetected in patients with CRF and yet 
be the stimulus for increased secretion of ANH. 
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I t  has recently been shown both in vivo and in vitro that approximately 
80% of ANH bioactivity is removed by l~h-~-k-T~ney (TTTT"-.A-dvanced renal disease 
may well be associated with a decrease in renal clearance, which together with 
stimulation of ANH secretion by volume overload is l ikely to be responsible 
for high IR-ANH levels. In this regard, the effects of renal failue on IR-ANH 
metabolism appear to be similar to those on the metabolism of the C-terminal 
portion of parathyroid hormone (18). In patients with CRF the contribution of 
decreased renal clearance may be important as suggestedby the significant 
correlation between IR-ANH levels and BUN in these patients (Fig. 4). 
The patients with ESRD studied had clinical evidence of volume overload 
and hemodialysis caused a significant decrease in their volume overload as 
documented by changes in blood pressure, heart rate and body weight (Table 1). 
This decrease in volume overload is probably the major cause for the 
significant decrease in IR-ANH levels during dialysis (Fig. 3). The very high 
levels of IR-ANH in patients with CRF and c l in ical ly  evident volume overload 
as well as the decrease in IR-ANH levels caused by the dialysis suggest that 
volume overload is the most important factor in regulation of ANH secretion in 
these patients. This is compatible with the results of the study in pediatric 
renal patients (16) and also with the documented effect of acute volume 
overload in animals (17) and man (10,11). Similar mechanisms probably cause 
increased levels of IR-ANH in patients and animals with congestive heart 
failure (9,11,19). 
An alternative explanation for the decrease in IR-ANH levels after the 
dialysis would be elimination of ANH from plasma by the dialyzer, either 
through f i l t ra t ion or degradation. The modest losses of circulating peptide 
during passage through the dialyzer are compatible with the present 
understanding of u l t raf i l t rat ion of peptides by the dialysis membrane (20). 
On the other hand a clearance of 21 mllmin cannot be solely responsible for 
the observed decrease in IR-ANH of more than 30% during dialysis. Removal of 
8% of ANH by the dialyzer is negligible when compared to the reported 50%-80% 
of removal of ANH in a single pass through the peripheral circulation (17,21). 
Another mechanism which could contribute to a decrease in IR-ANH levels 
following hemodialysis is dialysis related vasodilatation. This 
vasodilatation is explained by effects of acetate (22) and/or by increased 
interleukin-1 production (23,24). Decreased atrial pressure following this 
vasodilatation could cause a further decrease in ANH secretion. 
Volume overload is most probably not the only mechanism involved in the 
regulation of ANH secretion as suggested by the lack of correlation between 
the decrease in IR-ANH levels and the body weight loss during the dialysis. 
Our results in this regard are not in disagreement with those of Rascher 
et al. (16) although our interpretation of the data is different. In both 
studies there is no correlation between changes in body weight and decrease in 
IR-ANH levels during dialysis. Other factors involved in regulation of ANH 
secretion may include stimulation by vasopressors such as angiotensin II or 
vasopressin, changes in sympathetic tone or presence of immunoreactive but 
biologically inactive metabolites. 
In regard to possible vasopressin or angiotensin II mediated stimulation 
of ANH secretion, Katsube et al. (25) were able to show prominent increases in 
IR-ANH levels following administration of pharmacological doses of different 
pressor substances in rats. The changes in IR-ANH were closely correlated 
with changes in right atrial pressure. Nothing is known at the present about 
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the effects of physiologic doses of vasopressors on ANH secretion. I f  these 
doses are indeed stimulatory we could postulate that they may contribute to 
high levels of IR-ANH in some renal failure patients. Further increases in 
vasopressor levels after the dialysis could blunt the decrease in IR-ANH 
caused by decrease in volume overload. 
Increased sympathetic tone after the dialysis, implied by tachycardia and 
increased blood pressure, could be responsible for the increase in IR-ANH 
levels in one of our ESRD patients. Our preliminary data suggest that low 
dose infusion of epinephrine can cause a significant increase in IR-ANH 
levels (26). This effect is largely blocked by B-blocking agents (unpublished 
observation). 
I t  is possible that renal disease may cause the accumulation of 
biologically inactive fragments of ANH which are measured by the immunoassay. 
To date, the only reported circulating form of ANH in human plasma is 
28-amino-acid ANH (27). 
The physiologic significance of elevated IR-ANH levels in renal failure 
patients remains to be determined. In many of our patients the levels were 
high enough to cause a diuretic and natriuretic effect as documented in normal 
volunteers (11). The concentrations needed for a vasorelaxant effect are 
unknown. In rats with CRF, infusion of ANH causes a significant increase in 
glomerular f i l t ra t ion rate and decrease in blood pressure (28). The increased 
secretion of ANH in patients with renal failure may be an important adaptive 
response to volume retention and hypertension associated with renal disease. 
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